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1. Introduction  
The last two decades efforts have been made in investigation of genes that encode proteins 
involved in pathogenesis of emphysema and chronic obstructive pulmonary disease 
(COPD). So far, SERPINA1 gene which encodes protein alpha-1-antitrypsin (A1AT) is the 
only defined genetic risk factor associated with early development of emphysema.  
The A1AT is dominant protein of 1 electrophoretic fraction of serum proteins, whose main 
physiological role is to inhibit neutrophil elastase (NE) in the lower respiratory tract, and 
protect pulmonary connective tissue from NE released from triggered neutrophiles. 
Neutrophil elastase is serine protease that degrades elastin of the alveolar walls as well 
other structural proteins of a variety of tissues.  
Hereditary alpha-1-antitrypsin deficiency (A1ATD) is associated with retention of mutant 
A1AT polymers in hepatocytes which leads to decrease of circulating A1AT with less than 
15% of normal level in A1ATD homozygotes. Since the integrity of lung alveoli is 
maintained by proper circulating level of A1AT, severe deficiency of this protein was 
identified as genetic risk factor for emphysema and COPD. Clinical manifestation of 
emphysema in patients with A1ATD occurs in 3th decade in smokers and in the 5th decade 
in non-smokers (Larsson, 1978; Janus et al., 1985) and requires replacement therapy with 
purified A1AT pooled from donor plasma.  
Genetic epidemiologic studies show that A1ATD may affect 1 in about 1,500 individuals in 
Europe (De Serres, 2002). Approximately 3.4 million individuals of all racial subgroups are 
affected by A1ATD worldwide (De Serres, 2002). 
Liver disease in early childhood is second clinically significant consequence resulting from 
retention of mutant A1AT polymers in hepatocytes (Eriksson, 1986; Sveger, 1976). Clinically 
it is presents as neonatal cholestasis which may progress to juvenile chirosis or slowly 
progress to the liver disease in adults (Mahadeva and Lomas, 1998).  
In the early sixties of the last century, Laurell and Eriksson discovered that the absence of 
the electrophoretic 1-globulin pattern of serum is associated with A1AT deficiency (Laurell 
and Eriksson, 1963). At the same time was discovered an association between A1ATD and 
emphysema in relatively young patients in fourth decade of life (Eriksson, 1964; Lieberman, 
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1969). These observations suggested a significant role of A1ATD in pathogenesis of 
emphysema. The proteinase-antiproteinase hypothesis, established by Janoff (Janoff, 1985) 
still remains central in our understanding of the pathogenesis of lung disease. According to 
this hypothesis, emphysema in A1ATD arises from an imbalance of neutrophil elastase and 
A1AT as antielastase, which leads to inappropriate antielastase defense and the relatively 
excessive activity of neutrophil elastase and consequent degradation of elastin and other 
extracellular matrix components of the lower respiratory tract.  
However, only 1% of patients with COPD are A1ATD (Lieberman, et al., 1986), indicating 
that A1ATD alone is not sufficient to induce emphysema (Silverman, et al., 1989). The 
additional factor which may induce emphysema in A1ATD is inflammation, when elastin 
repair mechanisms are overwhelmed by a massive attack of elastase from triggered 
neutrophils and cigarette smoke. Studies of the genetic and environmental factors have 
shown a difference in the reduction of pulmonary function in A1ATD, indicating that 
additional genetic factors (modifier genes) may influence the pulmonary function in A1ATD 
subjects (Silverman et al., 1990). Also, the single-nucleotide polymorphisms (SNPs) were 
identified in the six haplotypes of the SERPINA1 gene, which controls synthesis of A1AT 
(Chappell, et al., 2006). Several environmental factors that accelerate the onset of symptoms 
in A1ATD patients, such as personal and second hand exposure to tobacco smoke in 
childhood, respiratory infections (Mayer et al., 2006), and higher exposures to ozone (Wood 
et al., 2009) have been also identified.  
In addition to the low circulating levels of A1AT in hereditary A1ATD, the risk of 
emphysema includes reduced antielastase activity. Functional inactivation of A1AT by 
oxidants present in cigarette smoke could impair antielastase defence in lower respiratory 
tract, and represent acquired A1AT inactivation. Furthermore, in hereditary A1ATD 
smoking could impair the function of A1AT both quantitatively and qualitatively. 
2. Alpha-1-antitrypsin 
Alpha-1-antitrypsine (A1AT) is the archetype of the serpin family of proteins. SERPINs 
(SERine Proteinase INhibitors) are the superfamily of structurally related proteins that control 
many physiological processes. A1AT is a highly polymorphic, acute-phase glycoprotein, 
synthesised in hepatocytes (Koj et al., 1978) and subsequently secreted into the plasma. 
Hepatic synthesis of this acute phase protein by SERPINA1 gene is under control of different 
cytokines, such as interleukin-1 (IL-1), tumour necrosis factors  (TNF) and most effectively 
the interleukin-6 family of cytokines (interleukin-6, leukaemia inhibitory factor, oncostatin M) 
(Richards and Gauldie, 1991). Besides liver, the small quantities of A1AT are produced by 
alveolar macrophages, circulating monocytes and intestinal, renal and lung-derived epithelial 
cells (Mornex et al., 1986; Carlson et al., 1988; Molmenti et al., 1993; Cichy et al., 1997; Mulgrew 
et al., 2004). Extra hepatic synthesis of A1AT is important in preventing tissue damage in the 
site of inflammation or injury. For instance, synthesis of A1AT in monocytes is up-regulated 
by inflammatory mediators such as IL-1 and TNF in lung tissue (Knoell et al., 1998). Serum 
level of A1AT is elevated in inflammation, trauma, and pregnancy.  
Healthy individuals produce 34 mg of A1AT per kilogram of body weight per day (Jones, 
1978). Normal reference interval for antigenic concentration of serum A1AT measured by 
nephelometry is 15-40 M (0.83-2.20 g/L) (ATS/ERS Statement, 2003). The threshold level of 
11 M (0.59 g/L) provides relevant antielastase protection of lower respiratory tract (WHO 
Meeting, 1996.). As a relatively small protein (52 kD), the mature A1AT is capable to diffuse 
into many organs. The concentration of A1AT in organs is lower than in plasma. Thus, 
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Olsen et al. (Olsen et al., 1975) reported that A1AT level in a bronchoalveolar lavage fluid of 
non-smokers is 7% of serum level, with a higher value (11%) in smokers. Also, total amount 
of A1AT in the lavage fluid of smokers was significantly greater than in non-smokers. The 
same authors reported about five times higher A1AT concentration in pulmonary alveolar 
macrophages in smokers in comparison to non-smokers. All these results suggest an 
increased A1AT concentration in the air spaces of the cigarette smokers.   
2.1 Structure and function of alpha-1-antitrypsin 
The mature A1AT protein is a single chain composed of 394 amino acids. The main 
characteristics of the protein are: Met358 residue at the active site, isoelectric point ranging 
from 4.4 to 4.6, and a total molecular weight of 52 kDa. Crystalographic analysis of the 
mature protein reveals that A1AT is a globular protein with tree N asparigynil-linked 
carbohydrate side chains on the external surface of the one end of the molecule 
(Loebermann et al., 1984). The side chains are composed of N-acetylglukosamine, mannose, 
galactose and sialic acid and they are N-linked to amino acids Asn46, Asn83 and Asn247. 
These carbohidrate side chains are on the outside surface of one-half of the elongated 
structure. The difference in carbohydrate side chains at position of Asn83 is responsible for 
the two major bands of A1AT when serum focused at pH 4-4.9 on thin-layer polyacrilamide 
gel. The internal structure of A1AT is highly ordered with 30 percent -helices and 40 
percent -pleated sheets. There are nine -helices (AI) and three -sheets (AI).  
Similar to other inhibitory serpins, A1AT is „suicide” or „single use” inhibitor that employs 
a unique and extensive conformational change in the process of inhibition of target 
proteases (Figure 1.). The hallmark of serpins is the reactive centre loop (RCL) that presents 
the key P1-P’1 methionine–serine bond as a pseudosubstrate for the cognate proteinase, 
neutrophil elastase (Johnson and Travis, 1978). The reactive centre loop of A1AT is highly 
stressed external loop protruding from the molecule with Met358-Ser359 in the active center. 
Inhibitory process begins by docking of the serpin and the protease, and formation of 
Michaelis complex. Like the other inhibitory serpins, the structure of the RCL is crucial for 
the ability of the inhibitor to undergo a „stressed to relaxed” (S→R) conformational change. 
The active A1AT is in metastable or „stressed form”, which is essential for inhibition of 
proteases. During the process of inhibition, A1AT is like mousetrap with spring-like shift 
from a metastable to a hyperstable state (Hunington et al., 2000; Carrell and Lomas, 2002). 
After the formation of Michaelis complex there are two possible different ending of the 
reaction. One is inactivation of protease, where serpin has undergone the S → R transition, 
and the protease hangs distorted at the base of the molecule. The other possibility is A1AT 
substrate-like behavior, where RCL forms the fourth -sheet, providing the opportunity for 
the protease to escape the conformational trap, leaving active protease and inactive cleaved 
serpin. Thus, in vivo, A1AT can exist in: native inhibitory conformation with an exposed 
RCL, latent conformation with a partially inserted RCL and non-inhibitory conformation. 
Non-inhibitory conformation of A1AT occurs in certain circumstances: when A1AT is in 
complex with neutrophil elastase, when the reactive center loop of A1AT is cleaved by non-
target proteinases, when reactive oxygen species oxidized A1AT, and when A1ATD variants 
form polymers.  
Moreover, A1AT non-inhibitory conformations show other biological effects. For instance, 
oxidized A1AT and the cleaved peptide fragment of A1AT stimulate monocyte activation, 
and A1AT-elastase complexes and polymeric A1AT are chemotactic for neutrophils (Banda 
et al., 1988; Dabbagh et al., 2001; Moraga and Janciauskiene, 2000; Moraga et al., 2001). 
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Fig. 1. Structure of alpha-1antitrypsin and reaction with target protease (modified from Law, 
et al., 2006) 
2.2 Physiological roles of alpha-1-antitrypsin 
The main physiological role of A1AT is protection of lower respiratory tract by inhibiting 
proteases released from triggered neutrophiles including neutrophil elastase, cathepsin G, 
and proteinase-3 (Carrell, 1986). The target proteases of A1AT derive from azurophilic 
granules of polymorphonuclear neutrophils which participate in lysosomal bacterial 
digestion and neutrophil migration through the extracellular matrix at the sites of 
inflammation. This protective role of A1AT occurs primarily extracellular. A1AT enters the 
lung from the circulation by passive diffusion (Stockley, 1984). Besides direct inhibition of 
NE, there are evidences that A1AT exhibits anti-inflammatory properties to suppress 
cigarette smoke induced production of tumor necrosis factor  (TNF) and matrix 
metalloproteinase 12 (MMP12) by alveolar macrophages, and subsequent inflammatory cell 
infiltration (Churg et al., 2007). Furthermore, studies have shown that native A1AT 
modulates function of immune cells, such as neutrophils (Bergin et al., 2010), monocytes 
(Janciauskiene et al., 2007), and T cells (Lu et al., 2006). Ex vivo and in vitro experiments have 
shown that endogenous A1AT in blood contributes to the suppression of proinflammatory 
cytokine synthesis (Pott et al., 2009). Thus, A1AT is an endogenous inhibitor of 
proinflammatory cytokine production in whole blood, and may participate in innate 
immune response to an inflammation-inducing stimulus. The recently discovered role of 
A1AT in prevention of emphysema is the inhibition of lung endothelial cell apoptosis due to 
inactivation of intracellular caspase-3 (Petrache et al., 2006a; Petrache et al., 2006b). 
Antiapoptotic role of A1AT in the lung in vivo and in vitro in micro vascular endothelial cells 
is associated with intracellular presence of A1AT. Lung endothelial cells don’t produce 
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A1AT and they take it. Sohrab et al. (Sohrab et al., 2009) showed that clathrin-mediated 
endocytosis predominantly regulates A1AT intracellular function in the lung endothelium, 
and might represent an important determinant of the serpin’s protection against 
development of cigarette smoke-induced emphysema. The uptake is severely affected by 
exposure to cigarette smoke extract in vitro and in vivo, probably directly influencing 
clathrin-mediated endocytosis. Furthermore, polymers of A1AT exhibit a marked decrease 
in lung endothelial cell uptake. Inhibition of A1AT uptake by cigarette smoke may further 
weaken the A1AT protective role in the lung. 
In the last decade other physiological roles of A1AT have been discovered, such as roles in 
atherogenesis (Talmud et al., 2003), angiogenesis (Huang et al., 2004), fibroblast 
proliferation, and procollagen synthesis (Dabbagh et al., 2001). 
2.3 Genetics of alpha-1-antitrypsin 
The alpha-1-antitrypsin is encoded by SERPINA1 gene (serpin peptidase inhibitor, clade A) 
located in proteinase inhibitor (Pi) locus on the long arm of chromosome 14q32.1 (Schroeder 
et al., 1985; Billingsley et al., 1993). The Pi locus is 12.2 kb long and consists of 4 coding 
exons, 3 non-coding exons and 6 introns (Figure 2.). At the 5 region of the SERPINA1 gene 
there are three non-protein coding exons (IA, IB, IC) which control gene transcription. Exons 
referred as exons II-V are coding and containing the sequence information that defines the 
protein itself. The start codon (ATG) for translational of the mRNA and the signal peptide 
are in exon II, and the stop codon (TAA) is in exon V, followed by the polyadenilatyon 
signal (ATTAA). The carbohydrate attachmnent site (Asn46, Asn83, Asn247) are coded for in 
exon II and III. The region coding for the reactive loop with the active inhibitory centre 
Met358 is within exon V.  
Following transcription, A1AT mRNA is translated on ribosome bound to the the rough 
endoplasmatic reticulum, producing a preprotein of 418 amino acids. The signal peptide of 
24 residues is removed during secretion into the cisterne of the rough endoplasmatic 
reticulum where the protein is glycosylated with high-mannose type carbohydrates, and 
folds into appropriate globular tree-dimensional configuration. Complete protein 
maturation is accomplished within the Golgi apparatus and protein is secreted.  
 
 
Fig. 2. Structure of the SERPINA1 gene (Crystal et al., 1989) 
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Hepatocytes and monocytes have two different promotors (Perlino et al., 1987) that operate 
via different mechanisms. The SERPINA1 gene in macrophages is transcribed from a 
macrophags-specific promoter located about 2,000 bp upstream of the hepatocyte-specific 
promoter. Transcription from the two SERPINA1 promoters is mutually exclusive; the 
macrophage promoter is silent in hepatocytes, and the hepatocyte promoter is silent in 
macrophages. In macrophages, two distinct mRNAs are generated by alternative splicing. In 
addition, Hafeez et al. (Hafeez et al., 1992) demonstrated that the SERPINA1 gene has 3 
monocyte-specific transcriptional initiation sites upstream from a single hepatocyte-specific 
transcriptional initiation site. Macrophages use these sites during basal and modulated 
expression. Hepatoma cells use the hepatocyte-specific transcriptional initiation site during 
basal and modulated expression, but also switch to transcription from the upstream 
macrophage transcriptional initiation sites during modulation by the acute phase mediator 
interleukin-6 (IL-6). 
2.4 Polymorphism of alpha-1-antitrypsin  
The A1AT coding gene SERPINA1 is a highly polimorphic, with more than 125 SNPs 
reported in public SNP databases (Entrez SNP). Protein variants of A1AT are classified by 
the Pi (Protese inhibitor) system and each variant is identified by migration on agarose gel 
electrophoresis. These differences in migration relate to variations in protein charge 
resulting from amino acid alterations (Fagerhol and Laurell, 1970; Cox, 1978). Isoelectric 
focusing in the narrow range of pH (4.2-4.9) has enabled identification of more A1AT 
variants then in agarose gel electrophoresis. The alleles were given symbols according to the 
relative electrophoretic mobility of the allele product, so anodal variants are marked with 
the first letters, and cathodal with last letters. All A1AT variants are categorized according 
to the serum level and functional activity as normal, deficient, null and dysfunctional.  
2.4.1 Normal A1AT variants 
Normal A1AT variants have normal serum level and functional activity to inhibit neutrophil 
elastase. More than 95% of normal variants are the „common” M1 (Ala213), M1 (Val213), M2 
and M3. Among Caucasians, M1 (Val213) is the most common, and M1 (Ala213), M2 and M3 
are less frequent. The „rare” normal variants with frequencies less than 1% are: M4, Balhambra, 
F, PStAlbans and XChirstchurch. Usually, rare variants are named by the birthplace of the oldest 
individual tested in pedegree. PiM homozygotes and heterozygotes are characterized by 
normal serum level of A1AT (20-50 M) and normal functional activity (ATS/ERS 
Statement, 2003).  
2.4.2 Deficient A1AT variants 
Deficient variants are associated with lower serum level of A1AT than normal variants. 
Several mutations associated with A1ATD have been identified, and the most common are Z 
and S alleles. Rare A1ATD variants are MMalton, MMineralSprings, MNichinan, MProcida, PLowell, SIiyama 
and others.  
Gene-mapping studies have shown that the PiZ allele probably arose in Northern Europe 
(Cox et al., 1985). Age estimates of A1AT variants based on microsatellite variation, suggest 
that the Z deficiency allele appeared 107 to 135 generations ago and could have been spread 
in neolithic times. Frequency of the Z allele shows a large variation in Caucasians, but is rare 
or absent in Asians and Africans (De Croo et al., 1991; Hutchison, 1998.). 
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The PiS deficiency allele has an older 279-generation to 470-generation age and from its high 
incidence on the Iberia peninsula it has been suggested that it could have originated in this 
region (Seixas et al., 2001).  
2.4.2.1 Z variant 
The Z variant represents a „classic“A1ATD variant and derives from M1 (Ala213) following a 
point mutation which is the same for the all Z individuals who are probably descendants of 
a single ancestral progenitor. The result of mutation is the substitution of a GAG that codes 
for Glu342 with an AAG that code for Lys342 (Nukiwa et al., 1987). The Z mutation perturbs 
the folding (Yu et al., 1995.) and structure of the protein (Lomas et al., 1993a). It distorts the 
relationship between the reactive centre loop and -sheet A, and the consequent 
perturbation in structure allows opening of -sheet A to favor partial loop insertion and 
formation of an unstable intermediate (M*) (Figure 3.). Then the patent -sheet A accepts the 
loop of another A1AT molecule to form a dimer (D) which then extends to form chains of 
loop-sheet polymer (P) (Lomas, et al., 1992; Elliott et al., 1996a; Lomas, 2000).  
 
 
Fig. 3. Formation of Z polymers (Lomas, 2005) 
Process of polymerization depends on concentration and temperature. Abnormality in 
posttranslational modification of protein causes accumulation of the A1AT polymers in the 
cisterna of the rough endoplsmatic reticulum with a drastic reduction in secretion rates. The 
abnormal protein accumulates in hepatocytes and forms inclusion bodies (aggregates) that 
are positive to diastase-resistant periodic acid Schiff (PAS-D) staining and visible on 
microscopy. The retained A1AT polymers are cytotoxic for hepatocytes and can cause a 
diverse liver damages, ranging from neonatal hepatitis to juvenile cirrhosis, and 
hepatocellular carcinoma in adults (Eriksson, et al., 1986). As a consequence of polymer 
accumulation, hepatocytes of PiZZ homozygote secrete only 10–15 % of normal quantity. 
PiMZ heterozygotes have about 50 % of normal A1AT circulating level. 
Besides low circulation level, the Z protein also less efficiently inhibits elastase (Ogushi, et 
al., 1987). Consequently, in PiZZ individuals, quantitative and qualitative defects of A1AT 
lead to early-onset COPD including emphysema and chronic bronchitis.  
A similar form of loop-sheet polymers in vivo with hepatic inclusions and plasma deficiency 
was found in two other variants, MMalton (Phe52 deleted) (Lomas et al., 1995) and SIiyama 
(Ser53→Phe) (Lomas et al., 1993b.), that are common in Sardinia and Japan, respectively. 
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A1AT polymers were also detected in bronchoalveolar lavage fluid (BALF) from PiZ 
homozygotes with emphysema. This conformational transition may further reduce the 
levels of functional proteinase inhibitor in the lungs, and consequently exacerbate lung 
tissue damage (Elliott et al., 1998).   
Studies of Parmar et al. (Parmar et al., 2002) and Mulgrew et al. (Mulgrew et al., 2004) 
showed that Z A1AT locally produced on the epithelial surface of the lung polymerizes and 
A1AT polymers demonstrate proapoptotic and proinflammatory effects. These studies also 
revealed that unlike M A1AT protein, Z A1AT protein polymerized at body temperature, 
and in addition of being an ineffective antiprotease inhibitor, might become a strong 
neutrophil chemoattractant, thus representing an ongoing source of inflammation in the 
lungs of individuals with A1ATD. Thus, polymerization of locally produced ZA1AT is a 
contributory factor to the lung inflammation experienced by those with A1AT deficiency 
and that standard antiprotease therapies may not address this problem. Other studies 
reported that even PiZZ patients with near-normal lung function had high concentrations of 
neutrophils on respiratory epithelial surfaces (Rouhani et al., 2000). Neutrophil burden in 
PiZZ and in PiMZ (on a lesser extent) is attributed to leukotriene B4 or IL-8 released from 
neutrophils or epithelial cells (Woolhouse et al., 2002; Malerba et al., 2006). Neutrophil 
accumulation in the lung of PiZZ deficient individuals is multifactorial and chemoattraction 
due to polymerized Z protein represents another potential cause of neutrophil dominated 
inflammation. These findings suggest a novel mechanism in pathogenesis of emphysema 
associated with Z antitrypsin deficiency. 
Lomas (Lomas, 2006) highlighted a possible role of Z mutant in systemic response to 
infection. In the case of invasion of pathogens, organism initiates a systemic inflammatory 
response that results in increased secretion of Z A1AT as acute phase protein, by 
hepatocytes. Factors such as: elevation of body temperature, increased concentration of 
mutant Z A1AT, and lower pH at the site of bacterial invasion of lung (Stockley and Burnett, 
1979) favor polymerization of mutant Z A1AT. Polymers possess chemotactic properties, 
which in turn amplify inflammatory response and enhance the recruitment of neutrophils. 
Excessive burden of neutrophils may cause increase of proinflamatory and proxidative 
factors.   
Therefore, a rational approach in therapy of A1ATD would be to inhibit the polymerization 
of the Z protein (intracellularly and extracellularly), accompanied by standard 
augmentation therapy. It is clear that in addition to increased level of A1AT above a 
putative therapeutic threshold, it is necessary to increase the secretion of active non-
polymerized form of Z protein. This approach could potentially ameliorate the liver disease, 
and defend respiratory epithelial surface, providing antielastase protection and avoiding the 
proinflammatory effects of polymerized Z A1AT.  
Currently, there is some progress in development of synthetic peptide designed to 
selectively inhibit Z polymerisation (Mahadeva et al., 2002; Parfrey et al., 2004; Chang et al., 
2006; Mallya et al., 2007; Chang et al., 2009).       
2.4.2.2 S variant 
In contrast to the Z allele, S causes only mild plasma deficiency. The genetic sequence of the S 
variant derives from M1 (Val213) as a result of a mutation which cause substitution of GAA that 
codes for Glu264 with an GTA that codes for Val264 (Owen et al., 1976; Yoshida et al., 1977).  
The single mutation of the S variant leads to spontaneous polymer formation, but slower 
than the Z variant, without affecting the ability to inhibit neutrophil elastase (Elliott, et al., 
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1996b; Mahadeva et al., 1999; Dafforn et al., 1999). The slower polymerization causes less 
retention of S variant in the liver, and hence the plasma levels are 60% of the normal M 
allele. Thus, carriers of S allele (PiSS, PiSZ and PiMS) have levels of 52%, 32% and 75% of 
normal level, respectively. Furthermore, Z A1AT forms heteropolymers with S A1AT 
(Mahadeva et al., 1999), which explains cases of hepatic cirrhosis in PiSZ patients (Cruz et 
al., 1975; Campra et al., 1973; Craig et al., 1975.). Also, PiSZ smokers are at significant risk of 
the development of COPD, while in nonsmoking individuals the PiSZ phenotype may 
confer little or no risk to develop COPD (Turino et al., 1996).  
2.4.2.3 Null A1AT variants 
Null variants are characterized by the modification of an important part of the gene with no 
detectable mRNA. Although extremely rare, they have been found in all populations. 
Frequencies of null variants among Caucasians are estimated to be less than 0.1%. Null-
allelic variants are denoted as Q0 rather than Pi. The Null mutations do not result in 
secreted protein or the formation of polymers. Subjects with Null mutations show 
significantly lower lung function values than PiSZ and PiZZ individuals, and they are at 
particularly high risk to develop emphysema (Cox and Levison, 1988; Fregonese et al., 2008). 
Early detection of Null carriers is important for preventive and therapeutic interventions. 
The PiNullBellingham differs from the normal M1 (Val213) gene by the mutation in exon II, 
where the codon for Lys217 (AAG) is altered to Stop codon (TAG) (Satoh et al., 1988). 
Homozygotes for PiNullBellingham have complete absence of A1AT, and develop premature 
emphysema much earlier than more common PiZZ individuals (Cook et al., 1994). The 
Nullisola di procida is caused by complete deletion of exons II-V of SERPINA1 gene (Takahashi 
and Crystal, 1990). The Nullgranite falls allele derives from the M1 (Ala213) by the deletion of a 
single base in exon II in the codon for Tyr160 (TAC) with deletion of the C. Consequently, 
there is 5' frame shift of the downstream nucleotides, moving the G form the next codon, 
Val161 GTC in place of the normal Tyr160 (Holmes et al., 1989). 
The Nullmattawa allele is a consequence of the insertion of a single nucleotide within the 
coding region of exon V, causing a 3' frameshift with generation of a premature stop signal 
(Curiel et al., 1989).   
Prins et al. (Prins et al., 2008) performed genotyping by direct sequencing of the SERPINA1 
gene coding region in patients with A1AT concentrations ≤1.0 g/L, and this approach 
allowed them to discover Q0soest and Q0amersfoort null alleles.  
2.4.2.4 Dysfunctional variants 
Dysfunctional A1AT variants are synthesized in normal quantities, but have altered protein 
function. The PiPittsburgh allele is a mutation which occurs at the A1AT active site, and 
represents an example of a mutation responsible for altered function of the gene product. 
A1AT becomes a potent inhibitor of thrombin and factor XI rather than of elastase, which 
results in a bleeding disorder (Lewis et al., 1978; Owen et al., 1983). 
3. Hereditary alpha-1-antitrypsin deficiency and emphysema 
The risk of developing early-onset emphysema caused by hereditary A1ATD is inversely 
correlated with the serum A1AT level (ATS/ERS Statement, 2003). Only PiZ homozygotes 
with severe decreased A1AT serum level, or carriers of M-like or Null alleles are at 
significant risk to develop panlobular emphysema with typical dilatation or destruction of 
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all lower lobules. However, the risk of COPD in PiMZ individuals is still controversial. 
Heterozygous, PiMZ individuals have moderately reduced serum levels A1AT, but whether 
they have increased risk of COPD is uncertain. Tarjan et al. (Tarjan et al., 1994) in 
longitudinal lung function study in heterozygous PiMZ subjects observed a decrease in 
elasticity and deterioration lung function parameters in comparison to those without 
A1ATD, which supports the concept of PiMZ phenotype being a risk factor for pulmonary 
emphysema development at a younger age. Dahl et al. (Dahl et al., 2002) found that PiMZ 
heterozygotes had a slightly greater rate of decrease in FEV1. Meta analysis by Hersh et al. 
(Hersh et al., 2004) has shown an increased odd of COPD in PiMZ individuals with 
suggestion that variability in study design and quality limits interpretation. Recent study 
(Sørheim et al., 2010) suggests that PiMZ individuals may be slightly more susceptible to the 
development of the airflow obstruction than PiMM individuals. 
3.1 Epidemiology of A1ATD 
The majority of the data regarding frequency and geographical distribution of severe 
A1ATD genotypes refer to the most frequent deficient variants PiZZ and PiSZ. Considering 
that severe A1ATD predisposes the development of emphysema that requires expensive 
diagnostic methods and treatment, it would be very useful to determine prevalence of 
severe A1ATD in every population.  
The most comprehensive study that has been performed on 200,000 Swedish newborns 
revealed the prevalence rate of PiZZ phenotype of approximately 1 in 1,600 newborns 
(Sveger, 1976). Despite the lack of reliable epidemiological studies and marked differences 
between countries, Blanco et al. (Blanco et al., 2006) estimated numbers of individuals 
carrying two most common deficiency alleles, Z and S in Europe. Highest prevalence of the 
PiZZ phenotype is in the Scandinavian Peninsula, Latvia and Denmark and progressively 
decreases towards the South and the East of Europe. While the highest prevalence of the 
PiSZ is in the Iberian Peninsula and it gradually decreases towards the North, South and 
East of the continent. Prevalence of the moderate PiMZ is highest in the South of the 
Scandinavian Peninsula, Baltic Republics, Denmark and the UK, and progressively 
decreases towards the East, South and North of the continent. The estimated prevalence of 
PiZZ, PiSZ and PiMZ in European adults was 1/4727, 1/1051 and 1/36 respectively, with 
large variation in different countries. In this regard, it was estimated that there are 124,594 
PiZZ, 560,515 PiSZ, and even 16 million PiMZ individuals in all Europe. Globally, A1ATD 
affects all major racial subgroups, and there are at least 116 million carriers (PiMZ and 
PiMS) and 3.4 million deficiency allele’s combinations (PiSS, PiSZ and PiZZ) worldwide (De 
Serres, 2002). According to these data, frequency of the Z allele is lowest in Far East Asia  
(0.04%), and highest in Northern Europe (1.53%), while the S allele is lowest in Far East Asia 
(0.07%), and highest in Southern Europe (5.64%).  
Although the epidemiological data indicate a large of number of A1ATD individuals 
worldwide, this condition is largely undiagnosed and exact prevalence of A1ATD in most 
population remains unknown. Owing to data from international registry of A1ATD, 
established in several countries, it was estimated that only 0.35% of severe A1ATD (PiZZ 
and PiSZ) are actually recognized (Luisetti and Seersholm, 2004). One of the reasons may be 
significantly delayed onset of symptoms. In 1994 Stoller at al. (Stoller et al., 1994) reported a 
mean interval of 7.2 years between initial symptom and first diagnosis.  A decade later, a 
decrement in the overall diagnostics of 5.6 years was noted (Stoller et al., 2005a), which was 
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attributed to the better education of physicians about recognising A1ATD. Authors 
concluded that despite this decrement in the overall diagnostics, underrecognition of 
individuals with A1ATD persisted. Under-recognition of A1ATD may be a part of a larger 
phenomenon of under-recognition of individuals with COPD. The second reason could be a 
low penetrance of the PiZ gene, so that the relationship between genotype and clinical 
phenotype is not strong. 
There are many benefits of early detection of A1ATD, such as avoidance of exposures to 
cigarette smoke and air pollution in prevention of pulmonary emphysema. Also, measure of 
prevention is protection from pneumonia, which is frequently reported in medical history of 
A1ATD patients with emphysema (McElvaney et al., 1997). In A1ATD patients, pulmonary 
infection further increases the risk of developing emphysema. Pulmonary infection favors 
increasing of elastase activity with subsequent destruction of lung due to compromised 
antiprotease defenses, and promotion of A1AT polymers due to elevated body temperature 
in inflammation. In this regard, it is very important to protect lung function of A1ATD 
individuals trough aggressive treatment of pulmonary infections and by vaccination with 
pneumococcal and influenza A vaccines. 
Data concerning genetic epidemiology of the rare A1ATD variants are incomplete, and 
therefore raise a suspicion that the prevalence of these variants might be higher than 2-4%, 
as previously considered, due to misclassification as Z variant (Luisetti and Seersholm, 
2004). Phenotyping by isoelectric focusing is often used to characterize 1AT deficiency, but 
this method may lead to misdiagnosis (e.g., by missing null alleles). Zorzetto et al. (Zorzetto 
et al., 2008) sequenced exons II, III, IV, and V of subjects whose are negative for Z and S 
alleles, and detected even 7% rare A1ATD alleles. Moreover, Prins et al. (Prins et al., 2008) 
have analyzed patients with A1ATD by sequencing of exons II, III, and V of the SERPINE1 
gene and reported that up to 22% of deficiency variants were missed by conventional 
diagnostic methods. 
3.2 Emphysema caused by A1ATD  
The main lung manifestations of severe A1ATD are emphysema and COPD (ATS/ERS 
Statement, 2003). In A1ATD-smokers, the first symptoms usually occur between 32 and 41 
years, with considerable variability in the time of onset of symptoms (Larsson, 1978; Tobin 
et al., 1983). 
Panlobular emphysema is dominant clinical manifestation in A1ATD patients, and affects 
the lower half of the lungs. Pulmonary vessels of the emphysematous lung appear fewer 
and smaller than normal (Stein et al., 1971). In severe A1ATD changes at the level of 
bronchioli such as bronchiolitis obliterans, bronchiolectasia, acute and chronic bronchiolitis 
and bronchiolitis with organizing pneumonia are more frequent than in emphysema 
without A1ATD (Theegarten et al., 1998).  
First representative study that included 124 patients with A1ATD and symptomatic 
emphysema (Brantly et al., 1988) showed predominance of male gender, ex-smoke status, 
levels of A1AT ≤ 5.5 M (0.3 g/L), and abnormalities in a lower zone distribution. About 
one third of patients had pulmonary hypertension. The lung function tests were typical for 
emphysema: the FEV1 and DLCO were dramatically reduced, and their annual rate of decline 
was greater than in general population. The cumulative probability of survival of the 
patients indicated a significantly shortened lifespan with a mean survival of 16% at 60 yr of 
age compared with 85% for normal persons.  
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The largest study ever conducted has been included 1,129 patients who participated in the 
National Heart, Lung, and Blood Institute (NHLBI) Registry of Individuals with Severe 
Deficiency of A1AT (McElvaney et al., 1997). Most frequent were PiZZ (97%), and very few 
PiSZ (1%), and rare variants (2%). Pulmonary function test results were consistent with 
emphysema. The pulmonary function impairment was moderate to severe, frequently 
associated with a bronchodilator response, but generally with preservation of the PaCO2 
until the development of severe airway obstruction. Medical history of lung function 
revealed that initial diagnoses included asthma (in 35% of participants), respiratory tract 
allergies (28%), pneumonia (43%), and chronic bronchitis (36%). The most frequent 
symptoms in A1ATD patients were dyspnea on exertion (in 84% of participants), self-
reported wheezing during respiratory tract infections (76%), and wheezing independent of 
infections (65%), usual cough (45%), and „annual” cough in phlegm episodes (52%). 
Significant number of patients who initially diagnosed as asthma had symptoms that 
suggest airway hyper-responsiveness such as cough and wheezing, responded to aerosol 
bronchodilator moderately (Eden et al., 1997).  It is interesting that a subgroup of 
individuals in the Registry with relatively normal lung function was younger, more likely to 
have never smoked and more likely to have come to medical attention owing to a family 
history of A1ATD.  
Cigarette smoking is associated with more accelerated decline of lung function and early 
development of emphysema in PiZZ individuals leading to a considerably reduced life 
expectancy (Larsson, 1978). A mortality study showed that emphysema was a major 
determinant of mortality in population of severe A1ATD patients (Stoller et al., 2005b). 
Negative impact of smoking on survival of A1ATD patients was demonstrated in two 
recently published studies. Tanassh et al. (Tanash et al., 2008) reported that PiZZ individuals 
who have never smoked and have been identified trough screening do not have an 
increased mortality risk in comparison to general Swedish population. Larger study which 
included 1,349 PiZZ individuals selected from the Swedish National AATD Registry 
showed that smokers with severe A1ATD had a significantly higher mortality risk than the 
general Swedish population (Tanash et al., 2010). The pulmonary emphysema has been 
more common in PiZZ smokers (78%) than in PiZZ never smokers (47%), and respiratory 
diseases have been main cause of death among PiZZ smokers (58%).   
3.3 Laboratory diagnosis of hereditary A1ATD   
Although being one of the most prevalent and potentially severe hereditary disorders, 
A1ATD still remains under-recognized. Affected individuals often visit several physicians 
before obtaining the correct diagnosis. The main reason is generally low knowledge about 
A1ATD among internists and respiratory therapists (Taliercio et al., 2010). Clinically 
relevant A1ATD is often caused by homozygous inheritance of the Z allele, but A1ATD can 
also be due to the combination of other rare deficient or null alleles at the Pi locus. Even 
moderate A1ATD in PiMZ heterozygote is associated with reduced pulmonary functions in 
individuals with clinically established COPD (Dahl et al., 2001). 
The guidelines of the American Thoracic Society and the European Respiratory Society 
(ATS/ERS Statement, 2003) recommend quantitative and qualitative laboratory testing for 
A1ATD for all patients with COPD, asthma, unexplained liver disease, and necrotizing 
panniculitis, as well as for asymptomatic subjects with persistent airflow limitation and 
siblings of A1ATD individuals. Laboratory testing of suspected A1ATD individuals involve 
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analysis of A1AT concentrations in serum and identification of specific alleles by 
genotyping or phenotyping. Therefore it is important to identify appropriate cutoff that 
balances costs of testing identification of deficiency alleles in the general population. 
Diagnostic algorithms for laboratory testing of the A1AT deficiency that were proposed 
(Snyder et al., 2006; Bornhorst et al., 2007; Miravitlles et al., 2010) should lead to improve 
diagnostics of A1ATD (Figure 4.). Initial testing involves quantification of A1AT 
concentrations and genotyping. Quantification of A1AT alone is not sufficient to diagnose 
genetic causes of A1ATD due to secondary causes of reduced concentration of A1AT in 
severe liver diseases, protein-losing enteropathies or nephrotic syndrome which may cause 
a general decrease of serum proteins. If serum level of A1AT lay in the expected range for 
the certain genotype, than the results and interpretation should be reported to physician. 
Qualitative analyses of A1ATD include two complementary methods, genotyping and 
phenotyping, each with advantages and disadvantages. Using conventional phenotyping of 
the A1AT by isoelectic focusing (IEF) necessarily leads to misdiagnoses of the null alleles 
(Klaassen et al., 2001). Therefore, the replacement of IEF with direct sequencing of the 
relevant parts of the SERPINA1 gene enables an efficient and reliable approach to reveal 
A1ATD patient. Direct sequencing of exons II, III and V of the SERPINA1 gene is the 
preferred method in initial phase of diagnostic algorithm for laboratory testing of A1ATD 
(Prins et al., 2008), as it allows detection of disease-associated A1AT allele combinations, 
including null alleles.  
However if quantitative result are in discrepancy with obtained genotype, laboratory should 
perform phenotype assay. Determination of phenotypes serve as complementary to the 
genetic assay, in order to clarify cases that cannot be detected by genotyping. Besides 
phenotyping, other techniques that can be considered as complementary include whole-
gene sequencing and the addition of other alleles to the melting curve genotype assay 
(Rodriguez et al., 2002).  
There are two approaches to assess the complementarity between serum level of A1AT and 
genotype result. Previously, the estimate was based on established threshold of A1AT 
serum levels for the most frequent A1AT phenotypes/genotypes in the general population. 
The various ranges for A1AT serum level of the most common phenotypes, which can be 
found in the literature, are results of different methods of quantification, different 
commercially available standards of A1AT, and samples size. (Brantly et al., 1991; Lee et al., 
2002; ATS/ERS Statement, 2003). Additional difficulty is the estimation of the ranges for 
rare phenotypes because it is difficult to collect a representative number of samples in a 
given population.  
In the context of these concerns, particular problem is the presence of inflammation in 
examined population. The A1AT is an acute phase protein and its production and secretion 
increases with inflammation. Thus, serum levels might be „falsely elevated” and are not 
reflecting the genotype, especially in moderate A1ATD. This was confirmed in a recent 
study which found that PiMZ individuals with a higher level of C-reactive protein (CRP, a 
sensitive marker of inflammation) had  higher level of A1AT than those with lower level of 
CRP (Zorzetto et al., 2008). Also, we should bear in mind that in healthy blood donors only 
26% of the variance of circulating A1AT level is explained by known SERPINA1 gene 
variants (Oakeshott et al., 1985). Recently, large population-based study on the Swiss 
SAPALDIA cohort (Senn et al., 2008) revealed that female gender, hormone intake, systolic 
blood pressure, age in men and in postmenopausal women, as well active and passive 
smoking were positively, whereas alcohol intake and body mass index (BMI) were  
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inversely correlated with serum A1AT levels, independent of CRP adjustment. The results 
of this study reflect a complexity of relationship between tobacco exposures, gender, 
circulating A1AT, systemic inflammatory status and lung function.   
Nowadays, the efforts are directed towards determination of the cut-off values with high 
specificity and sensitivity, in order to separate normal from deficient phenotypes. The value 
of A1AT serum level of 22 M (1, 2 g/L) has been determined as a reliable cut-off able to 
identify A1ATD with a specificity of 73% and a sensitivity of 97% (Corda et al., 2006). The 
lower value of 18.5 M (1.00 g/L) was able to detect heterozygous A1ATD (Simsek et al., 
2011), while cut-off value of 14.7 M (0.8 g/L) was proposed for detection of all patients 
who are at risk of A1ATD (Prins et al., 2008).    
  
 
Fig. 4. Alpha-1-antitrypsin deficiency−testing algorithm (Snyder et al., 2006) 
4. Oxidation of alpha-1-antitrypsin and emphysema 
Cigarette smoke and lung inflammation leads to proteolytic destruction of the lung 
parenchyma with characteristic loss of alveolar integrity and an enlargement of alveolar 
space (reviewed in: Sharafkhaneh et al., 2008). Oxidative stress, as a result of an imbalance 
between oxidants and antioxidants, plays a critical role in the pathogenesis of emphysema 
(Rahman, 2005; Janoff et al., 1983). There are two main significant sources of oxidants: 
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exogenous from cigarette smoke or air pollutants and endogenous from activated 
neutrophils and macrophages.  
Oxidative stress caused by cigarette smoke and airway inflammation together form a 
vicious circle. It has been shown that cigarette smoke-mediated oxidative stress induces the 
release of proinflammatory cytokine by activation of NF-kappaB and posttranslational 
modifications of histone deacetylase in macrophages (Yang et al., 2006). Chronic 
inflammation that persists in emphysema leads to the activation of macrophages and 
neutrophils (Finkelstein et al., 1995), which are a significant source of reactive oxygen 
species (ROS). When ROS overwhelm lung antioxidant defenses, the oxidative stress arises. 
Thus, cigarette smoke and activated macrophages/neutrophils represent considerable 
source of reactive oxygen species in emphysema. 
Cigarette smoke contains free radicals with tremendous oxidative power which serve as 
direct damaging agents and/or precursor of the other damaging substances. The main free 
radicals in cigarette smoke are superoxide (O2-), hydroxyl radical (OH), and hydrogen 
peroxide (H2O2) (Pryor, 1997).   
Harmful effects of oxidative stress are numerous: inactivation of antiproteases, disregulation 
of cell proliferation, induction of apoptosis, modulation the immune system, direct damages 
of proteins, lipids, and nucleic acids. The products of lipid peroxidation, protein oxidation, 
and nucleic acid oxidation have been shown in emphysema (Mohsenin, 1991; Sahin et al., 
2001; Hackett et al., 2010; Torres-Ramos et al., 2009; Deslee et al., 2009; Deslee et al., 2010).  
4.1 Oxidation of A1AT - structural and functional consequences  
A1AT is a protein susceptible to oxidation, and its exposure to pro-oxidative enzymes and 
chemicals results in their oxidation. Exposure of one A1AT molecule to oxidants results in 
oxidation of Met358 and Met351 residues to methionine sulfoxide (Johnson and Travis, 1979). 
Oxidation of both Met358 and Met351 significantly reduces the ability of A1AT to inhibit 
neutrophil elastase (Beatty et al., 1980; Taggart et al., 2000). Oxidation of Cys232 is far more 
likely to occur in oxidizing environments comparing with oxidation of exposed and reactive 
methionine residues (Griffiths et al., 2002). The structural and biological aspects of Cys232 
oxidation are still unknown.  
Methionine residues can be oxidized by cigarette smoke-derived oxidants (Pryor et al., 1984), 
produced in vivo  such as peroxide, hydroxyl radicals, chloramines, hypochloride, inducible 
nitric oxide, and peroxynitrite (Vogt, 1995), or with mineral dust (coal, amosite asbestos, silica, 
or titanium dioxide) (Li et al., 1997). Thus the oxidation of A1AT by cigarette smoke or free 
radicals in vivo could lead to a functional deficiency of A1AT and has been suggested as a 
mechanism contributing to the development of emphysema in non-deficient PiM individuals. 
Cigarette smoke-mediated oxidation of the Z mutant accelerates process of  polymerization, 
which further reduces defense of lung, increases neutrophil influx into the lungs (Alam et al., 
2011), and contributes to premature emphysema in PiZZ homozygotes who smoke.  
It has been reported that cigarette smoke oxidize A1AT (oxyA1AT), and reduces inhibitory 
activity of A1AT against elastase (Janoff et al., 1979) and caspase-3 (Petrache et al., 2006a). 
Substantial constituents of cigarette smoke that oxidise and inactivate A1AT include 
hydrogen peroxyde, nitrogen dioxide, transition metals, and products of lipid peroxidation 
initiated by cigarette smoke (reviewed in: Evans and Pryor, 1994). Inactivation of 
antielastase activity of A1AT is reversible and phenolic antioxidants prevented the 
suppression of serum elastase-inhibition by cigarette smoke (Carp and Janoff, 1978).  
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Another mechanism of A1AT oxidation is its oxidative inactivation in the microenvironment 
of inflammatory cells, at sites of acute or chronic inflammation. The lower airways of 
smokers are infiltrated with phagocitic cells. Induced neutrophils and alveolar macrophage 
release a spectrum of oxidants and pro-oxidative enzymes that may inactivate A1AT in their 
local environment. Increased release of proteases from triggered phagocytes and reduced 
antiprotease defense leads to damage of lung tissue (Carp and Janoff, 1980). 
Myeloperoxidase-dependent production of oxidants from neutrophils is increased in 
inflammation, and can cause significant damage of A1AT. Myeloperoxidase (MPO) is 
located in the azurophilic granules of the neutrophils, and plays an important role in the 
human immune system by killing bacteria and invading pathogen. Under certain 
circumstances, a MPO can be released into the extracellular space. In the presence of 
hydrogen peroxide and chloride ions, MPO produces hypochlorous acid (HOCl), the major 
strong oxidant which reacts readily with free amino groups to form N-chloramines. In vitro 
studies show that MPO inactivates purified A1AT trough oxidation of two methionine 
residues (Matheson et al., 1979; Summers et al., 2008). Hydrogen peroxide released from 
macrophages in the small airways of smokers synergistically with hydrogen peroxide from 
tobacco may contribute to the oxidative inhibition of A1AT (Cohen and James, 1982). 
Moreover, A1AT oxidized by the myeloperoxidase-hydrogen peroxide system (MPO-H2O2), 
in inflammation, promotes the formation of IgA-A1AT complexes, and consequently the 
elastase inhibitory activity of A1AT is reduced (Scott et al., 1999). 
Recent studies have shown that although oxyA1AT loses antielastase activity it gets new 
biological properties that may be important in the pathogenesis of certain diseases. Several 
studies have shown that oxyA1AT behaves as a proinflammatory stimulus. Moraga et al. 
(Moraga and Janciauskiene, 2000) revealed that oxyA1AT activates monocytes, which is 
reflected in significant elevation in monocyte chemoattractant protein-1, cytokine IL-6, and 
TNF expression, as well in increased activity of NADPH oxidase. Furthermore, oxyA1AT 
by activation of pro-oxidative NADPH oxidase may promote its own formation and thereby 
contributes to inflammation. OxyA1AT generated in the airway interacts directly with 
epithelial cells to release chemokines IL-8 and MCP-1, which in turn attracts macrophages 
and neutrophils into the airways (Li et al., 2009). The release of oxidants by these 
inflammatory cells could oxidize A1AT, perpetuating the cycle and potentially contributing 
to the pathogenesis of COPD.  
4.2 Oxidation of A1AT - clinical aspects  
Centrolobular emphysema in smokers as a clinical manifestation is strongly associated with 
functional deficiency caused by oxidation of A1AT. Several studies supported the 
mechanism by which tobacco smoke increased the risk of developing emphysema. 
According to this mechanism, cigarette smoke reduces protease inhibitory capacity, causing 
the increase of the lung vulnerability to elastolytic destruction and thereby increasing the 
risk for the development of emphysema (Carp et al., 1982; Janoff et al., 1983; Ogushi et al., 
1991). By losing the antiprotease ability and becoming pro-inflammatory stimulus, the 
oxyA1AT favors the development of clinical emphysema.  
OxyA1AT has a potential clinical significance in atherogenesis. Mashiba et al. (Mashiba et 
al., 2001) have revealed that A1AT produced and oxidized by macrophages, attaches to low 
density lipoprotein (LDL) in the intima of the arterial wall and contributes to the lipid 
accumulation in arterial wall cells in the early stage of atherogenesis. 
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In addition, reduction of antielastase activity was observed in hemodialysis patients 
(Hashemi et al., 2009). Furthermore, Honda et al. (Honda, et al., 2009) reported that serum 
levels of oxyA1AT positively correlated with myeloperoxidase in patients on hemodialysis, 
and could represent a useful marker for the estimation of the increasing carotid intima-
media thickness. They also found that oxyA1AT might be an independent predictor of 
protein-energy wasting in patients on hemodialysis. Oxidized A1AT was also detected in 
patients with Alzheimer's disease, heart failure, and in premature rupture of the fetal 
membrane (Choi et al., 2002; Banfi et al., 2008; Izumi-Yoneda et al., 2009). 
4.3 Perspective of the determination of oxidized A1AT 
Determination of oxyA1AT as biomarker is not used in routine practice, although it may be 
useful in assessment of pulmonary emphysema risk, and other pathological conditions 
associated with oxidative stress and inflammation. Our knowledge of the clinical 
significance of oxyA1AT is still insufficient, as well the optimal quantification of oxyA1AT.  
Previously used method for quantification of oxyA1AT was based on determination of 
elastase- (EIC) and trypsin inhibitory capacity (TIC) (Beatty et al., 1982). As oxyA1AT loses 
its ability to inhibit porcine elastase but retains antitrypsin activity, the increased TIC/EIC 
ratio correlates with degree of A1AT oxidation. Progress in oxyA1AT methodology includes 
development of immunochemical method (Ueda et al., 2002).  
Advanced methodology of quantification of oxyA1AT should be developed as a sensitive, 
specific method which would be suitable for routine practice. 
5. Conclusion  
The only proven genetic risk factor in pathogenesis of emphysema is severe alpha-1-
antitrypsin deficiency. However, several known and unknown genetic and environmental 
factors contribute to the differences in the susceptibility of A1ATD individuals to develop 
lung disease. Among the most important are cigarette smoke and air pollutants that could 
provoke oxidative stress and inflammatory response.  
So far, a lot of attention and efforts in A1ATD research was given to the deficient A1AT 
variants and A1AT polymerization, while the oxidation of A1AT protein has been generally 
overlooked. Non-deficient, heavy smokers may have normal serum level of A1AT, but with 
reduced functional activity due to functional deficiency caused by oxidation. The 
physiological role of oxyA1AT could be particularly important regarding growing evidence 
of different biological functions of A1AT that go beyond those usually linked to its 
antiprotease activities. Future studies will elucidate the role of A1AT oxidation in 
modulation of inflammation and tissue destruction which represent landmarks of 
emphysema, as well in modulation of augmentation therapy. 
The early recognition and diagnostics of A1ATD is the most important in terms of 
prevention and delay of the onset of symptoms of emphysema. The optimal approach in 
therapy of A1ATD would be to inhibit the polymerization of the Z protein (intracellular and 
extracellular) and prevent oxidative stress, accompanied by standard augmentation therapy.  
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